Skip to main content
Mineralocorticoid receptor blockers have demonstrated improved survival in class III-IV heart-failure patients (spironolactone) and post-acute myocardial infarction patients with systolic dysfunction heart failure (eplerenone).

Eplerenone Use for Mild Symptomatic Heart Failure?

Mineralocorticoid receptor blockers have demonstrated improved survival in class III-IV heart-failure patients (spironolactone) and post-acute myocardial infarction patients with systolic dysfunction heart failure (eplerenone).